TransCode Therapeutics Statistics
 Total Valuation
 RNAZ has a market cap or net worth of $9.17 million. The enterprise value is $1.75 million.
 Important Dates
 The next estimated earnings date is Friday, November 14, 2025, after market close.
 | Earnings Date | Nov 14, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
 RNAZ has 833,683 shares outstanding.
 | Current Share Class | 833,683 | 
| Shares Outstanding | 833,683 | 
| Shares Change (YoY) | n/a | 
| Shares Change (QoQ) | +383.95% | 
| Owned by Insiders (%) | 0.15% | 
| Owned by Institutions (%) | 4.19% | 
| Float | 749,140 | 
Valuation Ratios
  | PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | n/a | 
| Forward PS | n/a | 
| PB Ratio | 1.48 | 
| P/TBV Ratio | 1.48 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
 Financial Ratio HistoryEnterprise Valuation
  | EV / Earnings | n/a | 
| EV / Sales | n/a | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | n/a | 
Financial Position
 The company has a current ratio of 5.27
 | Current Ratio | 5.27 | 
| Quick Ratio | 4.82 | 
| Debt / Equity | n/a | 
| Debt / EBITDA | n/a | 
| Debt / FCF | n/a | 
| Interest Coverage | -1,150.02 | 
Financial Efficiency
 Return on equity (ROE) is -658.62% and return on invested capital (ROIC) is -237.91%.
 | Return on Equity (ROE) | -658.62% | 
| Return on Assets (ROA) | -139.89% | 
| Return on Invested Capital (ROIC) | -237.91% | 
| Return on Capital Employed (ROCE) | -218.61% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | -$3.51M | 
| Employee Count | 7 | 
| Asset Turnover | n/a | 
| Inventory Turnover | n/a | 
Taxes
  | Income Tax | n/a | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
 The stock price has decreased by -97.62% in the last 52 weeks. The beta is 1.52, so RNAZ's price volatility has been higher than the market average.
 | Beta (5Y) | 1.52 | 
| 52-Week Price Change | -97.62% | 
| 50-Day Moving Average | 11.74 | 
| 200-Day Moving Average | 41.84 | 
| Relative Strength Index (RSI) | 39.97 | 
| Average Volume (20 Days) | 424,154 | 
Short Selling Information
 The latest short interest is 58,698, so 7.04% of the outstanding shares have been sold short.
 | Short Interest | 58,698 | 
| Short Previous Month | 43,523 | 
| Short % of Shares Out | 7.04% | 
| Short % of Float | 7.84% | 
| Short Ratio (days to cover) | 0.16 | 
Income Statement
  | Revenue | n/a | 
| Gross Profit | n/a | 
| Operating Income | -14.65M | 
| Pretax Income | -24.60M | 
| Net Income | -24.60M | 
| EBITDA | -14.60M | 
| EBIT | -14.65M | 
| Earnings Per Share (EPS) | -$94.05 | 
 Full Income StatementBalance Sheet
 The company has $7.37 million in cash and n/a in debt, giving a net cash position of $7.37 million or $8.85 per share.
 | Cash & Cash Equivalents | 7.37M | 
| Total Debt | n/a | 
| Net Cash | 7.37M | 
| Net Cash Per Share | $8.85 | 
| Equity (Book Value) | 6.15M | 
| Book Value Per Share | 7.37 | 
| Working Capital | 6.68M | 
 Full Balance SheetCash Flow
 In the last 12 months, operating cash flow was -$14.35 million and capital expenditures -$13,370, giving a free cash flow of -$14.36 million.
 | Operating Cash Flow | -14.35M | 
| Capital Expenditures | -13,370 | 
| Free Cash Flow | -14.36M | 
| FCF Per Share | -$17.23 | 
 Full Cash Flow StatementMargins
  | Gross Margin | n/a | 
| Operating Margin | n/a | 
| Pretax Margin | n/a | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
 RNAZ does not appear to pay any dividends at this time.
 | Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | n/a | 
| Shareholder Yield | n/a | 
| Earnings Yield | -269.47% | 
| FCF Yield | -157.34% | 
 Analyst Forecast
 The average price target for RNAZ is $280.00, which is 2,445.46% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target | $280.00 | 
| Price Target Difference | 2,445.46% | 
| Analyst Consensus | Strong Buy | 
| Analyst Count | 1 | 
| Revenue Growth Forecast (5Y) | n/a | 
| EPS Growth Forecast (5Y) | n/a | 
 Stock ForecastsFair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
 The last stock split was on May 15, 2025. It was a reverse split with a ratio of 1:28.
 | Last Split Date | May 15, 2025 | 
| Split Type | Reverse | 
| Split Ratio | 1:28 | 
Scores
  | Altman Z-Score | n/a | 
| Piotroski F-Score | 2 |